ATRX mutation leads to decreased ATRX protein expression, and results in tumor genome instability, higher tumor mutation burden, and thus leading to increased sensitivity to chemotherapy, radiation therapy and immunotherapy agents 11, 12. This evidence concerns the gene ATRX and neoplasm.